Mexican Colorectal Cancer Research Consortium (MEX-CCRC): Etiology, Diagnosis/Prognosis, and Innovative Therapies.
Mexican Colorectal Cancer Research Consortium (MEX-CCRC)
antitumor immune response
colorectal cancer
colorectal cancer diagnosis
colorectal cancer prognosis
colorectal cancer therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
02
11
2022
revised:
22
12
2022
accepted:
22
12
2022
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
In 2013, recognizing that Colorectal Cancer (CRC) is the second leading cause of death by cancer worldwide and that it was a neglected disease increasing rapidly in Mexico, the community of researchers at the Biomedicine Research Unit of the Facultad de Estudios Superiores Iztacala from the Universidad Nacional Autónoma de México (UNAM) established an intramural consortium that involves a multidisciplinary group of researchers, technicians, and postgraduate students to contribute to the understanding of this pathology in Mexico. This article is about the work developed by the Mexican Colorectal Cancer Research Consortium (MEX-CCRC): how the Consortium was created, its members, and its short- and long-term goals. Moreover, it is a narrative of the accomplishments of this project. Finally, we reflect on possible strategies against CRC in Mexico and contrast all the data presented with another international strategy to prevent and treat CRC. We believe that the Consortium's characteristics must be maintained to initiate a national strategy, and the reported data could be useful to establish future collaborations with other countries in Latin America and the world.
Identifiants
pubmed: 36768437
pii: ijms24032115
doi: 10.3390/ijms24032115
pmc: PMC9917340
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Support Program for Research Projects and Technological Innovation (PAPIIT)-UNAM
ID : IN-217021
Organisme : Support Program for Research Projects and Technological Innovation (PAPIIT)-UNAM
ID : IN-212722
Organisme : Consejo Nacional de Ciencia y Tecnología (CONACyT)
ID : A1-S-10463
Références
Cancer Cell Int. 2019 Apr 02;19:80
pubmed: 30983885
Cell Rep. 2019 Feb 12;26(7):1965-1977.e4
pubmed: 30759403
FASEB J. 2013 Nov;27(11):4547-60
pubmed: 23907435
Gastroenterol Rep (Oxf). 2018 May;6(2):83-92
pubmed: 29780595
Front Oncol. 2021 May 26;11:594200
pubmed: 34123772
Front Oncol. 2019 Jul 25;9:669
pubmed: 31404273
Cancer Immunol Res. 2017 May;5(5):385-396
pubmed: 28385737
Int J Mol Sci. 2021 Jul 19;22(14):
pubmed: 34299314
J Cancer. 2022 Sep 25;13(13):3404-3414
pubmed: 36313038
World J Gastroenterol. 2019 Jan 14;25(2):151-162
pubmed: 30670906
Gut. 2013 Jun;62(6):933-47
pubmed: 23481261
Nutrients. 2021 Jun 29;13(7):
pubmed: 34209683
Mediators Inflamm. 2019 Jul 10;2019:2056085
pubmed: 31360118
Adv Exp Med Biol. 2016;937:53-69
pubmed: 27573894
J Immunol. 2019 Jul 15;203(2):532-543
pubmed: 31142601
Sci Rep. 2018 Sep 18;8(1):13974
pubmed: 30228361
Int J Mol Sci. 2021 Oct 18;22(20):
pubmed: 34681866
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Drug Discov Today. 2016 Jan;21(1):190-199
pubmed: 26456577
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018 Jul;35(7):1238-1246
pubmed: 29847212
Int J Cancer. 2016 Jun 15;138(12):2915-21
pubmed: 26840624
Cell Death Dis. 2021 Feb 4;12(2):155
pubmed: 33542244
Cells. 2020 Mar 04;9(3):
pubmed: 32143413
Signal Transduct Target Ther. 2018 Nov 30;3:31
pubmed: 30510778
Mediators Inflamm. 2020 Apr 21;2020:5062506
pubmed: 32377161
Ann Oncol. 2009 May;20 Suppl 4:61-3
pubmed: 19454465
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36
pubmed: 21864702
Nat Genet. 2022 Jul;54(7):985-995
pubmed: 35726067
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
J Immunol. 2012 Oct 15;189(8):3905-13
pubmed: 22972922
Int J Mol Sci. 2020 Oct 22;21(21):
pubmed: 33105843
Exp Ther Med. 2019 May;17(5):3748-3754
pubmed: 31007730
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
World J Gastroenterol. 2010 May 21;16(19):2421-7
pubmed: 20480530
Tumour Biol. 2017 Apr;39(4):1010428317695945
pubmed: 28443472
Nat Immunol. 2001 Nov;2(11):1061-6
pubmed: 11668338
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
J Exp Clin Cancer Res. 2019 Dec 16;38(1):492
pubmed: 31842958
PLoS Pathog. 2017 Sep 22;13(9):e1006649
pubmed: 28938014
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
J Cancer. 2016 Jul 25;7(12):1632-1644
pubmed: 27698900
Sci Rep. 2017 Jan 20;7:40373
pubmed: 28106049
Front Cell Infect Microbiol. 2019 Jan 08;8:437
pubmed: 30671387
Int J Mol Sci. 2020 Mar 20;21(6):
pubmed: 32244885
Front Oncol. 2020 Aug 18;10:1037
pubmed: 33014767
Cancers (Basel). 2018 Sep 19;10(9):
pubmed: 30235866
Cancer Res. 2014 Aug 15;74(16):4258-69
pubmed: 24906621
Curr Mol Pharmacol. 2022;15(4):620-646
pubmed: 34488607
Genes (Basel). 2021 Feb 09;12(2):
pubmed: 33572255
Clin Gastroenterol Hepatol. 2012 Jun;10(6):639-45
pubmed: 22289873
Int J Cancer. 2019 Dec 1;145(11):3126-3139
pubmed: 31407335
Food Chem Toxicol. 2018 Jan;111:153-165
pubmed: 29128614
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Gastroenterology. 2015 May;148(6):1244-60.e16
pubmed: 25575572
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674255
Mol Cancer. 2020 Jan 22;19(1):12
pubmed: 31969156
Drug Resist Updat. 2010 Feb-Apr;13(1-2):44-56
pubmed: 20176501
Gac Med Mex. 2019;155(5):447-452
pubmed: 32091022
Front Oncol. 2020 Dec 16;10:573343
pubmed: 33425726
Mutagenesis. 2017 Jan;32(1):139-149
pubmed: 27789654
Transl Oncol. 2020 Dec;13(12):100871
pubmed: 32950931
J Oncol. 2020 Apr 29;2020:5701527
pubmed: 32411238
Nat Rev Clin Oncol. 2017 May;14(5):297-315
pubmed: 27995949
Food Chem Toxicol. 2020 Dec;146:111786
pubmed: 33038453
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
Int J Cancer. 2007 Dec 1;121(11):2373-80
pubmed: 17893866
Clin Gastroenterol Hepatol. 2014 May;12(5):756-64
pubmed: 23920032
J Nutr. 2020 Apr 1;150(4):663-671
pubmed: 31758189
Front Nutr. 2017 Dec 05;4:59
pubmed: 29259973
Nat Rev Clin Oncol. 2021 May;18(5):261-279
pubmed: 33469195
Mediators Inflamm. 2019 Mar 7;2019:1971698
pubmed: 30983878
PLoS Negl Trop Dis. 2017 Jun 26;11(6):e0005708
pubmed: 28650985
J Dig Dis. 2019 Sep;20(9):447-459
pubmed: 31240835
Mod Pathol. 2003 May;16(5):491-504
pubmed: 12748256
Nutr Cancer. 2021;73(8):1429-1439
pubmed: 32715775
J Cancer. 2018 Jan 1;9(2):239-249
pubmed: 29344269
Front Oncol. 2020 Mar 31;10:413
pubmed: 32296643
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33919941
Oncol Lett. 2020 Jul;20(1):455-464
pubmed: 32565970
PLoS One. 2013;8(1):e53916
pubmed: 23349764
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
Food Chem Toxicol. 2016 Jul;93:20-31
pubmed: 27117919
Nat Med. 2009 Sep;15(9):1016-22
pubmed: 19701202
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
Int J Biol Sci. 2014 Aug 24;10(9):948-56
pubmed: 25210492
Biosci Rep. 2018 Oct 22;38(5):
pubmed: 30266743
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
Int J Mol Sci. 2018 Nov 05;19(11):
pubmed: 30400561